drugset
drugset / Trial / NCT01157377

Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

NCT01157377 ↗

Phase 2 Completed 160 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and efficacy of AGN-214868 in patients with idiopathic overactive bladder (IOAB) and urinary incontinence.

Timeline

Start
2010-10
Primary completion
2013-02
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject SENREBOTASE Protein / enzyme biologic 500 ng Other
Subject SENREBOTASE Protein / enzyme biologic 1000 ng Other
Subject SENREBOTASE Protein / enzyme biologic 2000 ng Other
Subject SENREBOTASE Protein / enzyme biologic 6000 ng Other
Subject SENREBOTASE Protein / enzyme biologic 18000 ng Other
Subject SENREBOTASE Protein / enzyme biologic 60000 ng Other

Indications

overactive bladder